GlassScriptPhysician profile
Thuan P Le
NPI 1396842704
$142,595.38
in general payments reported to CMS, 2019-2025
34 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $17K · 2021: $14K · 2022: $24K · 2023: $36K · 2024: $3,511 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $9,946 · Travel and Lodging: $4,576 · Consulting Fee: $2,938 · Education: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,900.83 |
| Food and Beverage | $9,945.65 |
| Travel and Lodging | $4,576.31 |
| Consulting Fee | $2,938.00 |
| Education | $1,177.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $40,236.31 | 2019-2023 | Kimyrsa, Orbactiv, Rezzayo |
| Abbvie INC. | $19,681.36 | 2021-2025 | |
| Cumberland Pharmaceuticals, INC. | $18,448.53 | 2019-2025 | Vibativ |
| Merck Sharp & Dohme LLC | $17,063.07 | 2019-2025 | Dificid, Recarbrio, Zerbaxa |
| Ferring Pharmaceuticals INC. | $12,202.91 | 2021-2024 | Rebyota |
| Grt US Holding, INC. | $9,406.92 | 2020-2022 | |
| Cipla USA INC. | $7,098.51 | 2019-2022 | |
| Insmed, INC. | $4,874.55 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $4,191.68 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Astellas Pharma US INC | $3,912.63 | 2019-2024 | Cresemba |
| Paratek Pharmaceuticals, INC. | $1,313.74 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $859.46 | 2020-2025 | Egrifta, Trogarzo |
| La Jolla Pharmaceutical Company | $714.97 | 2020-2025 | Xerava, Zevtera, Xacduro |
| Smith+Nephew, INC. | $482.49 | 2019-2020 | |
| Shionogi INC | $365.70 | 2021-2025 | Fetroja |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $273.42 | 2019-2025 | |
| Tetraphase Pharmaceuticals, INC. | $220.38 | 2019-2020 | |
| Abiomed | $193.31 | 2024 | Impella |
| Octapharma USA, INC. | $137.72 | 2023-2024 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Aimmune Therapeutics, INC. | $125.76 | 2023-2024 | |
| Amarin Pharma, INC. | $112.07 | 2019 | |
| Averitas Pharma INC. | $83.47 | 2023-2025 | Qutenza |
| Tactile Systems Technology INC | $77.30 | 2020-2024 | Entre Plus, Flexitouch Plus |
| Genentech, INC. | $76.67 | 2019 | |
| Janssen Scientific Affairs, LLC | $76.50 | 2022 | |
| Allergan, INC. | $68.06 | 2020 | |
| Nabriva Therapeutics, Plc | $63.85 | 2020-2021 | |
| Pfizer INC. | $59.06 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $46.42 | 2025 | Myfembree |
| Janssen Biotech, INC. | $45.63 | 2022-2023 | Symtuza |
| Grifols USA, LLC | $38.54 | 2024 | Gamunex-C |
| Mayne Pharma Commercial LLC | $33.18 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $11.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuan Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.